A Phase 3 interventional study of IgPro20 in Primary Immune Deficiency, sponsored by CSL Behring. Completed at 4 sites in United States. Open to participants aged 2 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-04-02.
Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Primary Immunodeficiency Diseases by CSL Limited — none open to participants now, none under way, none of them phase 3. Primary Immunodeficiency Diseases · CSL Limited.
Among the 14 studies in Primary Immunodeficiency Diseases by CSL Limited, this one is the 10th largest by enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2008, is one of 9 in phase 3, and was the 6th registered.
211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.
Browse Primary Immunodeficiency Diseases studies →None of the 14 studies in Primary Immunodeficiency Diseases by CSL Limited is open now. The open studies under Primary Immunodeficiency Diseases, anywhere →
Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21 is below the median of 36 across 125 interventional studies indexed under Primary Immunodeficiency Diseases.
Median enrollment 25 across the 13 interventional studies, 27 across the 1 observational. Of the 14 that completed or were terminated, 7 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under CSL Behring, one of the names counted as CSL Limited. Under that name alone:
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Primary Immunodeficiency Diseases by CSL Limited, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether a long-term use of a new human immunoglobulin G with proline (IgPro) is safe and effective in the treatment of primary immunodeficiency.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The IgPro20 dose will be the same as in the previous pivotal study ZLB04_009CR (NCT00419341) infused subcutaneously weekly or twice a week (in the latter case, half of a weekly dose will be used)
Biological: IgPro20
Also known as: IgG with Proline
Annualized Rate of Serious Bacterial Infection (Intention-to-Treat Population)
The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days. Acute serious bacterial infections included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess.
Time frame: For the duration of the study, up to approximately 104 weeks
Annualized Rate of Serious Bacterial Infection (Per-Protocol Efficacy Population)
The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days. Acute serious bacterial infections included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess.
Time frame: For the duration of the study, up to approximately 104 weeks
Annualized Rate of Any Infection
The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.
Time frame: For the duration of the study, up to approximately 104 weeks
Trough Levels of Total Immunoglobulin G (IgG) Serum Concentrations
Mean of individual median total IgG trough concentration.
Time frame: Before infusion at Weeks 1, 24, 48, 72, and 96
Number of Days Out of Work / School / Kindergarten / Day Care or Inability to Perform Normal Activities Due to Infection
Time frame: For the duration of the study, up to approximately 104 weeks
Annualized Rate of Days Out of Work / School / Kindergarten / Day Care or Inability to Perform Normal Activities Due to Infection
The annualized rate was based on the total number of days out of work / school / kindergarten / day care or inability to perform normal activities due to infection, and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.
Time frame: For the duration of the study, up to approximately 104 weeks
Number of Days of Hospitalization Due to Infection
Time frame: For the duration of the study, up to approximately 104 weeks
Annualized Rate of Hospitalization Due to Infection
The annualized rate was based on the total number of days of hospitalization due to infection and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.
Time frame: For the duration of the study, up to approximately 104 weeks
Use of Antibiotics for Infection Prophylaxis and Treatment
Annualized rate of days with antibiotics for infection prophylaxis and treatment.
Time frame: For the duration of the study, up to approximately 104 weeks
Rate of All AEs by Relatedness and Severity
The rate of AEs was the number of AEs over the number of infusions administered. At least possibly related AEs included possibly related AEs, probably related AEs, and related AEs. Mild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities.
Time frame: For the duration of the study, up to approximately 104 weeks
Relatedness and Severity of All AEs (Percentage of Total AEs)
At least possibly related AEs included possibly related AEs, probably related AEs, and related AEs. Mild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities.
Time frame: For the duration of the study, up to approximately 104 weeks
Number of Subjects With Any Temporally Associated Adverse Event (AE) Within 24 or 72 Hours After an Infusion
AEs were considered temporally associated if they occurred between the start of infusion and within 24 or 72 hours after the end of infusion.
Time frame: Within 24 or 72 hours after each infusion
Rate of Temporally Associated AEs Within 24 or 72 Hours of an Infusion
The rate of AEs was the number of AEs over the number of infusions administered. AEs were considered temporally associated if they occurred between the start of infusion and within 24 or 72 hours after the end of infusion.
Time frame: Within 24 or 72 hours after each infusion
Number of Subjects Reporting Mild, Moderate, or Severe Local AEs
In addition to the standard MedDRA System Organ Class (SOC) AE assignments, the category of 'local reactions' was defined to provide the possibility for a combined analysis of local reactions and included AEs of infusion site oedema, infusion site reaction, injection site pain, injection site rash, and injection site reaction. Mild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities.
Time frame: For the duration of the study, up to approximately 104 weeks
Number of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Vital Signs
Vital signs included blood pressure (systolic and diastolic), heart rate, and body temperature.
Time frame: At weeks 1, 12, 24, 36, 48, 60, 72, 84, and 96
Number of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Routine Laboratory Parameters
Routine laboratory parameters included hematology, blood chemistry, and urinalysis parameters.
Time frame: At Week 1, and study completion (approximately 104 weeks)
Number of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Viral Safety Markers
Viral safety markers included human immunodeficiency virus (HIV)-1, HIV-2, hepatitis A virus (HAV), HBV, HCV, and parvovirus B19.
Time frame: At Week 1, and study completion (approximately 104 weeks)
| Milestone | IgPro20 |
|---|---|
| Started | 21 |
| Completed | 16 |
| Not completed | 5 |
| Withdrew: Adverse event | 1 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Withdrawal by subject | 3 |
The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days. Acute serious bacterial infections included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess.
| infections per subject year | IgPro20 |
|---|---|
| Annualized Rate of Serious Bacterial Infection (Intention-to-Treat Population) | 0.06 |
The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.
| infections per subject year | IgPro20 |
|---|---|
| Annualized Rate of Any Infection | 2.38 |
The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days. Acute serious bacterial infections included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess.
| infections per subject year | IgPro20 |
|---|---|
| Annualized Rate of Serious Bacterial Infection (Per-Protocol Efficacy Population) | 0.03 |
Mean of individual median total IgG trough concentration.
| g/L | IgPro20 |
|---|---|
| Trough Levels of Total Immunoglobulin G (IgG) Serum Concentrations | 11.98 ± 3.65 |
| days | IgPro20 |
|---|---|
| Number of Days Out of Work / School / Kindergarten / Day Care or Inability to Perform Normal Activities Due to Infection | 6.67 ± 13.49 |
The annualized rate was based on the total number of days out of work / school / kindergarten / day care or inability to perform normal activities due to infection, and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.
| days per subject year | IgPro20 |
|---|---|
| Annualized Rate of Days Out of Work / School / Kindergarten / Day Care or Inability to Perform Normal Activities Due to Infection | 4.28 |
| days | IgPro20 |
|---|---|
| Number of Days of Hospitalization Due to Infection | 0.857 ± 2.726 |
The annualized rate was based on the total number of days of hospitalization due to infection and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.
| days per subject year | IgPro20 |
|---|---|
| Annualized Rate of Hospitalization Due to Infection | 0.55 |
Annualized rate of days with antibiotics for infection prophylaxis and treatment.
| days per subject year | IgPro20 |
|---|---|
| Use of Antibiotics for Infection Prophylaxis and Treatment | 83.87 (5 to 673) |
The rate of AEs was the number of AEs over the number of infusions administered. At least possibly related AEs included possibly related AEs, probably related AEs, and related AEs. Mild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities.
| AEs per infusion | IgPro20 |
|---|---|
| All | 0.661 |
| Unrelated | 0.137 |
| At least possibly related | 0.524 |
| Mild | 0.575 |
| Moderate | 0.076 |
| Severe | 0.010 |
At least possibly related AEs included possibly related AEs, probably related AEs, and related AEs. Mild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities.
| percentage of total AEs | IgPro20 |
|---|---|
| Unrelated | 20.7 |
| At least possibly related | 79.3 |
| Mild | 87.0 |
| Moderate | 11.5 |
| Severe | 1.5 |
AEs were considered temporally associated if they occurred between the start of infusion and within 24 or 72 hours after the end of infusion.
| participants | IgPro20 |
|---|---|
| AEs within 24 hours | 21 |
| AEs within 72 hours | 21 |
The rate of AEs was the number of AEs over the number of infusions administered. AEs were considered temporally associated if they occurred between the start of infusion and within 24 or 72 hours after the end of infusion.
| AEs per infusion | IgPro20 |
|---|---|
| AEs within 24 hours | 0.322 |
| AEs within 72 hours | 0.575 |
In addition to the standard MedDRA System Organ Class (SOC) AE assignments, the category of 'local reactions' was defined to provide the possibility for a combined analysis of local reactions and included AEs of infusion site oedema, infusion site reaction, injection site pain, injection site rash, and injection site reaction. Mild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities.
| participants | IgPro20 |
|---|---|
| Total | 19 |
| Mild | 16 |
| Moderate | 3 |
| Severe | 0 |
Vital signs included blood pressure (systolic and diastolic), heart rate, and body temperature.
| participants | IgPro20 |
|---|---|
| Number of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Vital Signs | 0 |
Routine laboratory parameters included hematology, blood chemistry, and urinalysis parameters.
| participants | IgPro20 |
|---|---|
| Number of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Routine Laboratory Parameters | 0 |
Viral safety markers included human immunodeficiency virus (HIV)-1, HIV-2, hepatitis A virus (HAV), HBV, HCV, and parvovirus B19.
| participants | IgPro20 |
|---|---|
| Number of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Viral Safety Markers | 0 |
Collected over From the time of informed consent until study completion, up to approximately 121 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IgPro20 | — | 4/21 (19%) | 21/21 (100%) |
| Event | IgPro20 |
|---|---|
| CellulitisInfections and infestations | 1/21 |
| PneumoniaInfections and infestations | 1/21 |
| Thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/21 |
| DiarrheaGastrointestinal disorders | 1/21 |
| Event | IgPro20 |
|---|---|
| SinusitisInfections and infestations | 14/21 |
| Injection site reactionGeneral disorders | 10/21 |
| Infusion site reactionGeneral disorders | 9/21 |
| NasopharyngitisInfections and infestations | 7/21 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 6/21 |
| Upper respiratory tract infectionInfections and infestations | 6/21 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/21 |
| FatigueGeneral disorders | 5/21 |
| BronchitisInfections and infestations | 5/21 |
| Influenza-like illnessGeneral disorders | 4/21 |
| Age, Continuous(years) | IgPro20 |
|---|---|
| Mean | 42.4 ± 18.53 |
| Age, Customized(participants) | IgPro20 |
|---|---|
| >= 2 to < 12 years | 1 |
| >= 12 to < 16 years | 1 |
| >= 16 to < 65 years | 16 |
| >= 65 years | 3 |
| Sex: Female, Male(Participants) | IgPro20 |
|---|---|
| Female | 15 |
| Male | 6 |
The record gives a start of Jun 2008, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2013, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hizentra
Primary Immunodeficiency Diseases →